SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 14, 2007
Blonder Tongue Laboratories, Inc.
(Exact Name of registrant as specified in its charter)
Delaware 1-14120 52-1611421
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation) Identification No.)
One Jake Brown Road, Old Bridge, New Jersey 08857
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (732) 679-4000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[_] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
On December 18, 2007 the Company issued a press release announcing its
receipt of a Warning Letter from the American Stock Exchange, dated December 14,
2007. The press release is attached hereto as Exhibit 99.1 and is incorporated
into this Item 7.01 by reference.
Item 9.01. Financial Statements and Exhibits.
(a) The following exhibits are filed herewith:
Exhibit 99.1 Press Release dated December 18, 2007.
Forward Looking Statements
This report contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. These statements are neither
promises nor guarantees, are based upon assumptions and estimates that might not
be realized and are subject to risks and uncertainties that could cause actual
results to differ materially from those in the forward looking statements. These
risks and uncertainties include, but are not limited to, the ability of the
Company to identify qualified independent directors to serve on the Board of
Directors of the Company. There are a number of factors that may cause actual
results to differ from these forward-looking statements, including the success
of marketing and sales strategies and new product development, the price of raw
materials, and general economic and business conditions. Other risks and
uncertainties that may materially affect the Company are provided in the
Company's annual reports to shareholders and the Company's periodic reports
filed with the Securities and Exchange Commission from time to time, including
reports on Forms 10-K and 10-Q. Please refer to these documents for a more
thorough description of these and other risk factors.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BLONDER TONGUE LABORATORIES, INC.
By: /s/ Eric Skolnik
Eric Skolnik
Senior Vice President
and Chief Financial Officer
Date: December 18, 2007
3
EXHIBIT INDEX
Exhibit No. Description
Exhibit 99.1 Press Release of Blonder Tongue Laboratories, Inc.
dated December 18, 2007 regarding receipt of a Warning
Letter from the American Stock Exchange.
4
Exhibit 99.1
